Author: Christensen, K.; Ren, H.; Chen, S.; Cooper, C. K.; Young, S.
Title: Clinical evaluation of BD Veritor™ SARS-CoV-2 and Flu A+B Assay for point-of-care (POC) System Cord-id: wq02ppl4 Document date: 2021_5_4
ID: wq02ppl4
Snippet: Differential diagnosis of COVID-19 and/or influenza (flu) at point of care is critical for efficient patient management and treatment for either of these diseases. Clinical performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 & FluA+B (Veritor SARS-CoV-2/Flu) triplex assay was characterized. The performance for SARS-CoV-2 detection was determined using two hundred and ninety-eight (298) specimens from patients reporting COVID-19 symptoms within 7 days from symptom onset (DSO) i
Document: Differential diagnosis of COVID-19 and/or influenza (flu) at point of care is critical for efficient patient management and treatment for either of these diseases. Clinical performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 & FluA+B (Veritor SARS-CoV-2/Flu) triplex assay was characterized. The performance for SARS-CoV-2 detection was determined using two hundred and ninety-eight (298) specimens from patients reporting COVID-19 symptoms within 7 days from symptom onset (DSO) in comparison with Lyra(R) SARS-CoV-2 RT-PCR Assay (Lyra SARS-CoV-2). The Veritor SARS-CoV-2/Flu Assay met the FDA EUA acceptance criterion with 95% overall agreement for SARS-CoV-2 test when compared to Lyra SARS-CoV-2. The performance for Flu A and Flu B detection was determined using 75 influenza-positive and 40 influenza-negative retrospective specimens in comparison with the previously FDA cleared BD Veritor System for Rapid Detection of Flu A+B (Veritor Flu). The Veritor SARS-CoV-2/Flu also demonstrated 100% agreement with the Veritor Flu.
Search related documents:
Co phrase search for related documents- accurate detection and administration emergency: 1, 2, 3, 4
- active infection and administration emergency: 1, 2
Co phrase search for related documents, hyperlinks ordered by date